Neuraxpharm, the Germany-based central nervous system specialist, has struck a deal that will see it market domestically a range of medical cannabis products made by Israel’s Panaxia Labs.
The collaboration will start in Germany – which Neuraxpharm said was “Europe’s largest cannabis market” – but was “expected to expand to additional countries,” with the agreement including a “mutual
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?